skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension

Original Research

(2593) Views  (1332) Full article downloads

Authors: Thomas K Mundorf, Steven H Rauchman, Robert D Williams, Ricardo Notivol, Brinzolamide/Timolol Preference Study Group

Published Date October 2008 Volume 2008:2(3) Pages 623 - 628
DOI: http://dx.doi.org/10.2147/OPTH.S4088

Thomas K Mundorf1, Steven H Rauchman2, Robert D Williams3, Ricardo Notivol4, Brinzolamide/Timolol Preference Study Group5

1Mundorf Eye Center, Charlotte, NC, USA; 2North Valley Eye Medical Group, Mission Hills, CA, USA; 3Taustine Eye Center, Louisville, KY, USA; 4Alcon, Barcelona, Spain; 5Ophthalmology Clinics, USA

Purpose: To determine patient preference of and ocular discomfort with fixed combination brinzolamide/timolol compared with fixed combination dorzolamide/timolol.

Methods: In a prospective, double-masked, randomized, active-controlled, crossover, multicenter study, patients received 1 drop of brinzolamide/timolol and dorzolamide/timolol in both eyes on consecutive days in random order. Ocular discomfort was rated 1 minute after instillation of each medication, and preference was noted on Day 2. Adverse events, if any, were solicited at each visit.

Results: 127 subjects with ocular hypertension or open-angle glaucoma were included in the intent-to-treat analysis. Of the 106 subjects who expressed a drug preference, 79.2% preferred brinzolamide/timolol (p < 0.0001). Ocular discomfort scores were significantly higher with dorzolamide/timolol than brinzolamide/timolol (2.9 vs 1.4, respectively; p < 0.0001). Significantly more patients reported ocular pain and discomfort after dorzolamide/timolol instillation and transient blurred vision after brinzolamide/timolol instillation.

Conclusions: Patients with ocular hypertension or open-angle glaucoma preferred the brinzolamide/timolol fixed combination over the dorzolamide/timolol fixed combination. This is likely due to the greater ocular discomfort associated with dorzolamide/timolol. The differences in preference, discomfort, and adverse events are likely attributable to formulation differences given the similarities of the active ingredients. Stronger patient preference for brinzolamide/timolol may lead to better therapeutic compliance.

Keywords: brinzolamide/timolol, dorzolamide/timolol, patient preference, ocular discomfort, open-angle glaucoma or ocular hypertension








Readers of this article also read:

Nano rough micron patterned titanium for directing osteoblast morphology and adhesion
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Perindopril: the evidence of its therapeutic impact in hypertension
The Nordic health registers – an important source when evaluating the safety of antidepressants during pregnancy
Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises
Erratum - Intracellular heavy metal nanoparticle storage
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Primary care for diabetes mellitus: perspective from older patients